论文部分内容阅读
Objective: Linsitinib, a novel dual insulin-like growth factor 1 (IGF-1R)/insulin receptor (IR) kinase inhibitor in phase Ⅲ clinical trial, was investigated the reversal of multidrug resistance (MDR) induced by ATP-binding cassette (ABC) transporters.